Continue Both Medications and Consider Dose Optimization
You should continue both Farxiga 10 mg and Mounjaro 10 mg, as these glucose readings indicate suboptimal glycemic control that warrants therapy intensification rather than discontinuation. A fasting glucose of 126 mg/dL (7.0 mmol/L) and a recent reading of 145 mg/dL (8.1 mmol/L) suggest your current regimen is not achieving adequate glycemic targets, and both medications provide complementary mechanisms with proven cardiovascular and renal benefits beyond glucose lowering 1, 2.
Why Continue Both Medications
The combination of an SGLT2 inhibitor (Farxiga) and a GLP-1 receptor agonist (Mounjaro) is evidence-based and recommended by major guidelines 2, 3. These agents work through different mechanisms:
- Farxiga (dapagliflozin) increases urinary glucose excretion and provides cardiovascular and kidney protection independent of glucose lowering 4
- Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that enhances insulin secretion, suppresses glucagon, and promotes weight loss 5, 6
The 2022 ADA/KDIGO consensus explicitly supports combining SGLT2 inhibitors with GLP-1 receptor agonists, noting "emerging data suggest promise for combined effects on cardiorenal outcomes" 2.
Consider Dose Escalation of Mounjaro
Your current Mounjaro dose of 10 mg weekly may be suboptimal. The maximum approved dose is 15 mg weekly, and clinical trials demonstrate dose-dependent improvements in glycemic control 5, 6, 7:
- Tirzepatide 15 mg produces HbA1c reductions of -2.13% to -2.58% compared to -1.59% to -1.87% with 10 mg 5, 7
- Higher doses achieve greater rates of normoglycemia without significantly increased hypoglycemia risk 6
Escalate Mounjaro from 10 mg to 15 mg weekly if tolerated, as this is the standard titration pathway 8, 9. The dose should be increased after at least 4 weeks at the current dose.
Maintain Farxiga at Current Dose
Continue Farxiga 10 mg daily without modification. This is the standard dose for cardiovascular and renal protection 4. The glucose-lowering efficacy of SGLT2 inhibitors is reduced at lower eGFR levels, but the cardiorenal benefits persist 2. Your glucose readings do not indicate excessive glucose lowering that would warrant dose reduction.
Additional Considerations
Assess for Metformin
If you are not currently taking metformin and your eGFR is ≥30 mL/min/1.73 m², metformin should be added as first-line therapy 1. Metformin remains foundational therapy and can be safely combined with both Farxiga and Mounjaro.
Monitor for Side Effects
- Gastrointestinal symptoms (nausea, diarrhea) are common with GLP-1 receptor agonists, especially during dose escalation 5, 9
- Genital mycotic infections occur in approximately 6% of patients on SGLT2 inhibitors 2
- Euglycemic ketoacidosis is rare but serious; withhold Farxiga during prolonged fasting or surgery 1, 4
Set Realistic Glycemic Targets
Your fasting glucose should ideally be <100-130 mg/dL depending on individual factors. The current readings of 126-145 mg/dL suggest an HbA1c likely above 7%, warranting intensification 3.
Common Pitfalls to Avoid
- Do not discontinue SGLT2 inhibitors based solely on glucose readings - their primary value is cardiorenal protection, not just glucose lowering 1, 2
- Do not stop at subtherapeutic doses of tirzepatide - most patients require 10-15 mg for optimal benefit 5, 6
- Do not delay intensification - therapeutic inertia is a major barrier to achieving glycemic control 3
The evidence strongly supports continuing both medications with consideration for Mounjaro dose escalation to 15 mg weekly to achieve better glycemic control while maintaining the proven cardiovascular and renal benefits of this combination therapy 2, 3, 5.